Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1 FDA Emergency Use Authorization Statement.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. The European Commission (EC) will review the CHMP recommendation and is soon expected to make a final decision. PAXLOVID is currently approved or authorized for conditional or emergency use in more than 70 countries to treat COVID-19.

Marketing 75

Marketing Production Drugs Licensing 75

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Nirmatrelvir has shown consistent in vitro antiviral activity against the following variants: Alpha, Beta, Delta, Gamma, Lambda, Mu, and Omicron BA.1, The additional 3.7 million treatment courses are planned for delivery by early 2023. .

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Tuesday, December 20, 2022 - 04:30pm. Pfizer oral treatment remains available to eligible U.S. NEW YORK, December 20, 2022 -- Pfizer Inc. NYSE: PFE) announced today that the U.S.

Drugs 69

Drugs Licensing Licensing Containment 69

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. This agreement, negotiated with the Health Emergency Preparedness and Response Authority (HERA) of the EC, is in addition to the bilateral agreements Pfizer has previously signed with 17 EU Member States. .

Licensing 40

Licensing Licensing Drugs Manufacturing 40

Drug Discovery World

OCTOBER 14, 2022

Arndt Aspe r ger , Senior Applications Scientist , Bruker Daltonics and M ei ke Hamester , Vice President Label-Free Technologies , Bruker Daltonics , examine how challenges in mass spectrometry for high-throughput screening can be overcome using a label-free approach. . The rapid evolution of HTS to meet industry demand .

Drugs 52

Drugs In-Vitro Development Production 52